Charting Disruption 2025: Advancing Healthcare – Global X ETFs – 2.12.25

November 27, 2022

Overview:

Title: Charting Disruption 2025: Advancing Healthcare

Date: Wednesday, February 12, 2025

Time: 1:00 PM Eastern Standard Time

Duration: 1 hour

Register Now:

Already Registered?

*First Name
*Last Name
*Email
*Work Phone
Cell Phone
*Company
*Title
*State
*Type of Advisor
CFP #
IWI (CIMA, CIMC or CPWA) #
Zip Code for IWI Submission
CFA Institute ID
Please submit any questions for our speakers.

*I am a financial professional. I understand that this event is for financial professionals only, and I may be contacted by the sponsor.

Summary:

Now On Demand

In today’s rapidly evolving market landscape, thematic investing offers a strategic approach to capture structural changes reshaping our world. Rather than traditional sector or geographic allocations, this approach targets companies positioned to benefit from transformative trends driven by technological innovation, demographic shifts, and evolving consumer behaviors.

In healthcare, a continually growing aging population will further strain overburdened healthcare systems. Disruptive technologies show promise in alleviating healthcare demands, while also helping people live better for longer. These themes not only represent significant market opportunities but also reflect fundamental changes in how society operates and interacts with technology.

Join us as we explore these key investment themes:

Aging Population: The global population is rapidly aging, with the number of adults aged 65 and older projected to double to 1.7 billion by 2053. In the U.S., the 65 and older group currently accounts for approximately 37% of all healthcare spending, despite representing 16% of the population.
Tech-Enabled Health: Gen-AI has the potential to accelerate drug discovery, leading to cost efficiencies and more affordable medicines. By 2032, drug-discovery gen-AI tools can add $41 billion in software spending and reduce a new drug’s time to market.
Genomics: Currently, revenues from genomic medicines derive from treatments for 15 illnesses, seven of which comprise 78% of revenues. By 2030, genomic medicines for 80 illnesses are expected to generate revenues.

View the full Charting Disruption experience: globalxetfs.com/charting-disruption

Accepted for 1 CFP^® / IWI / CFA CE Credit

Speaker:

Arelis Agosto Director of Research & Strategy Global X ETFs

Arelis (Lis) is the Director of Research & Strategy at Global X, where she leads research initiatives across the company’s full product lineup. She has been with Global X since 2022, where she started as a Research Analyst covering healthcare-related funds in the Thematic Growth suite. Prior to joining Global X, she worked as a Senior Healthcare Analyst at Third Bridge, focusing on U.S. life sciences, diagnostics, biotech, pharmaceutical services, and animal health. Lis holds a BA from Babson College in Business, with a concentration in Global Businesses Management.